Clinical trial
Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss
NCT00352846 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00352846 |
|---|---|
| Title | Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss |
| Official title | Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss in Non-Hodgkin's Lymphoma Patients Receiving Chemotherapy |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma, Lymphoma |
| Intervention type | Drug |
| Interventions | Zoledronic Acid, Vitamin D, Calcium Carbonate |
| Enrollment | 135 |
| Start date | Jan 1, 2006 |
| Primary completion | Sep 1, 2011 |
| Completion | Sep 1, 2011 |
| First posted | Jul 17, 2006 |
| Last update posted | Jul 2, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: